within Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IB03_Indium111inAntiovariumca;

model Indium111inAntiovariumca
  extends Pharmacolibrary.Drugs.ATC.V.V09IB03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>Indium111inAntiovariumcarcinomaAntibody</td></tr><tr><td>ATC code:</td><td>V09IB03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Indium (111In) antiovariumcarcinoma antibody is a radiopharmaceutical consisting of an antibody against human ovarian carcinoma cells, labeled with radioactive indium-111. It is used as a diagnostic imaging agent to localize ovarian carcinoma metastases or recurrences. It is not currently approved for routine clinical use, primarily used experimentally or in investigational settings.</p><h4>Pharmacokinetics</h4><p>No specific published pharmacokinetic parameters found in the literature for indium (111In) antiovariumcarcinoma antibody in humans. General estimates are reported for radiolabeled monoclonal antibodies in adult cancer patients.</p><h4>References</h4><ol><li><p>Macklis, RM, et al., &amp; Burakoff, SJ (1988). Biodistribution studies of anti-Thy 1.2 IgM immunoconjugates: implications for radioimmunotherapy. <i>International journal of radiation oncology, biology, physics</i> 15(2) 383â€“389. DOI:<a href=\"https://doi.org/10.1016/s0360-3016(98)90020-7\">10.1016/s0360-3016(98)90020-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3403319/\">https://pubmed.ncbi.nlm.nih.gov/3403319</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Indium111inAntiovariumca;
